March 20, 2026 7:26am

Represents aspects of sentiment’s share pricing

C&GT stocks barely ascended after Thursday’s negative open

Pre-open Signals: a little too hinky i.e., suspect for me

Remember that overnight action in futures don't necessarily translate into actual trading in today’s regular stock market session.

Never leave retail investor uninformed … I say what others won’t, so you can KNOW what others can’t!

 

 

Say/write less, mean more …

RMi Closing Bell: Sudden and a barely come-back of cell and gene therapy equities

… https://www.regmedinvestors.com/articles/14354

RMi Research Note: Harvard Apparatus GT (OTCQB: HRGN): dives -$0.28 on 1 share traded …

https://www.regmedinvestors.com/articles/13812

I chose to speak-up when many analysts, brokers and commentators have shut-up!

 

Friday: The pre-open Dow futures are DOWN -0.29% or (-135 points), the S&P futures are DOWN -0.39% or (-25 points) and the Nasdaq futures are DOWN -0.53% or (-130 points)

  • U.S. stock futures are reeling Friday, 3/20
  • European equities and bourses bounced back 
  • Asia Pacific markets mostly decline

Economic Data: None

 

The major averages are still on pace to post their 4th losing week in a row, however the S&P 500 dive -0.4% and Dow enter Friday’s session down -1.2%, while the Nasdaq has shed -0.1%. Both the Dow and Nasdaq are also nearing correction territory. The Dow is 8.3% below its record close set Feb. 10, and the Nasdaq sits nearly 8% away from its all-time closing high reached Oct. 29.

 

Henry’omics: We need to more than consider the market’s setting to grasp the micro re “our” universe of cell and gene therapy companies

  • Thursday: The Dow closed DOWN -203.72 points or -0.44%, the S&P closed DOWN -18.21 points or -0.27% while the Nasdaq closed DOWN -61.73 points or -0.28%
  • Wednesday: The Dow closed DOWN -768.11 points or -1.63%, the S&P closed DOWN -91.39 points or - 1.36% while the Nasdaq closed DOWN -327.107 points or -1.46%
  • Tuesday: The Dow closed UP +47.40 points or +0.10%, the S&P closed UP +16.72 points or +0.25% while the Nasdaq closed UP +105.35 points or +0.47%
  • Monday: The Dow closed UP +387.94 points or +0.83%, the S&P closed UP +67.19 points or +1.01% while the Nasdaq closed UP +268.819 points or +1.22%
  • Last Friday: The Dow closed DOWN -119.38 points or -0.26%, the S&P closed DOWN -40.43 points or -0.61% while the Nasdaq closed DOWN -206.62 points or -0.94%
  • Last week: The S&P 500 was down -1.6%, the Dow -2% and the Nasdaq was down -1.3%.
  • The previous week: The S&P 500 was down -2%, the Dow -0.3% and the Nasdaq was down -1.2%.
  • February: the Dow inclined +0.2%, the Nasdaq dived -3.3% and S&P 500 declined -1%.

 

Q1/26 – Q1 – March – 6 positive and 8 negative closes

  • February – 1 market holiday, 11 positive and 8 negative closes
  • January – 2 holiday, 2 neutral, 9 negative and 9 positive closes 

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

  • As I wrote above … Pre-open Signals: a little too hinky i.e., suspect for me

 

The BOTTOM LINE: Welcome to my world of defining the “grey’ in our universe!

The Dow and Nasdaq are nearing correction territory…

  • The Dow is -8.3% below its record close set Feb. 10, and the Nasdaq sits nearly 8% away from its all-time closing high reached Oct. 29.
  • The S&P 500 holding around 5% off of its all-time high

My thoughts … OPEN the wallet – BUY - selectively!

Investors has been looking for further insight into sector earnings; the Q4 and FY25 earnings reporting cycle. So far …

  • Tuesday - 2/24 – AxoGen (AXGN), Beam Therapeutics (BEAM) and Supernus Therapeutics (SUPN)
  • Wednesday – 2/25 – MiMedx (MDXG), Ionis Pharmaceuticals (IONS) and Sarepta Therapeutics (SRPT)
  • Thursday – 2/26 – Intellia Therapeutics (NTLA), Wave Life Sciences (WVE), Mesoblast (MESO), Vericel (VCEL) and BioLife Solutions (BLFS)
  • Monday – 3/2 uniQure NV (QURE)
  • Thursday - 3/5 Regenxbio (RNX)
  • Tuesday – 3/10 – BioNTech, SE (BNTX)
  • Monday – 3/16 -Agenus (AGEN)
  • Thursday – 3/19 – Cellectis Sa (CLLS) and Solid Biosciences (SLDB)

 

Welcome to my world of defining the “grey’ in our universe!

  • I hate to be so negative or contrarian but, this is a NO spin zone and facts and truth are its products; I can always be WRONG but, I am mostly EARLY!
  • if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

March – 3rd week

  • 3/19 – Thursday closed positive with 20 incliners, 18 decliners and 2 flats
  • 3/18 – Wednesday closed negative with 3 incliner, 35 decliners and 2 flats
  • 3/17 - Tuesday closed positive with 25 incliners, 14 decliners and 1 flat
  • 3/16 - Monday closed positive with 27 incliners, 10 decliners and 3 flats

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.